세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 보고서(2025년)

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

체외분비 기능부전(EPI) 치료 및 진단 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.8%로 성장할 전망이며, 83억 2,000만 달러로 성장이 예측됩니다. 예측 기간 성장은 원격 의료 및 원격 모니터링, 데이터 분석과 AI, 환자 교육 및 지원, 규제 변경 및 상환 정책에 기인하고 있습니다. 예측 기간 주요 동향에는 개별화 치료 접근법, 신규 치료법 개발, 저침습 진단, 공동 케어 모델 등이 있습니다.

당뇨병의 유병률 증가는 향후 체외분비 기능부전(EPI) 치료 및 진단 시장의 확대를 촉진할 것으로 예측됩니다. 당뇨병은 혈당 상승(고혈당)을 특징으로 하는 만성질환으로 체내에서 인슐린이 충분히 분비되지 않거나 인슐린을 효과적으로 사용하지 못하는 것이 원인입니다. 췌장 효소 보충 요법(PERT)을 포함한 EPI 치료는 당뇨병 및 EPI 환자 모두에서 영양 흡수를 높이고 더 나은 혈당 조절을 지원할 수 있습니다. 예를 들어 2024년 6월 국민보건서비스(NHS England)는 2023년 당뇨병 예비군으로 진단받은 사람의 수가 2022년 306만 5,825명에서 18% 증가하여 361만 5,330명이 되었다고 보고했습니다. 40세 미만에서는 당뇨병 예비군이 2022년 17만 3,166명에서 2023년 21만 6,440명으로 25% 가까이 증가했습니다. 이 당뇨병 인구 증가가 EPI 치료 및 진단 수요를 촉진하고 있습니다.

소화기 질환의 급증은 당면한 체외분비 기능부전(EPI) 치료 및 진단 시장의 확대를 견인할 것으로 예측됩니다. 소화관 질환에는 소화를 관장하는 기관을 포함한 소화관에 영향을 미치는 다양한 병세가 포함됩니다. 위장질환 관리는 효소 부족을 시정하고 효과적인 영양 소화를 촉진하는 체외분비 기능부전(EPI) 치료 및 진단에 크게 의존하고 있습니다. 예를 들어 2023년 6월 현재 캐나다에 본부를 둔 비영리단체 Crohn's and Colitis Canada는 2023년에는 32만 2,600명 이상의 캐나다인이 염증성 장질환(IBD)을 앓았으며, 인구의 약 0.82%를 차지한 것으로 평가했습니다. IBD의 유병률은 앞으로도 계속될 것으로 예측되어 2035년에는 약 47만 명의 캐나다인이 IBD에 이환될 것으로 예상되며, 이는 인구의 약 1.1%, 즉 국민의 약 91명 중 1명이 이환하게 됩니다. 그 결과 소화기 질환의 이환율 증가가 체외분비 기능부전(EPI) 치료 및 진단 시장 성장의 원동력이 될 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 체외분비 기능부전(EPI) 치료 및 진단 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 성장률 분석
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 치료법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 영양 관리
• 췌장효소 보충요법(PERT)
• 라이프 스타일 변경 접근
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 혈액검사
• 자기 공명 영상(MRI)
• 내시경적 초음파 검사(EUS)
• 컴퓨터 단층 촬영(CT) 스캔
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 약 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 제네릭
• 브랜드
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 직접 입찰
• 소매 약국
• 타사 유통업체
• 기타 유통 채널
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 홈케어
• 진단센터
• 조사 및 학술 기관
• 기타 최종 사용자
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 영양 관리별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 식생활의 변경
• 영양 보조 식품
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 췌효소보충 요법(PERT)별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 캡슐 제형
• 정제 처방
• 분말 제형
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 라이프스타일 변경 접근 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 체중 관리
• 신체 활동의 추천 사항
• 금연 프로그램

제7장 지역별 및 국가별 분석

• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 체외분비 기능부전(EPI) 치료 및 진단 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 체외분비 기능부전(EPI) 치료 및 진단 시장 : 경쟁 구도
• 체외분비 기능부전(EPI) 치료 및 진단 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Janssen Pharmaceuticals Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Sanofi SA
• AstraZeneca plc
• Abott Laboratories
• Medtronic plc
• Solvay SA
• Laboratory Corporation of America Holdings(Labcorp)
• Organon group of companies Metagenics LLC
• Allergan plc
• Chiesi Farmaceutici SpA
• Codexis Inc.
• Nordmark Arzneimittel GmbH & Co. KG
• ChiRhoClin Inc.
• Digestive Care Inc.
• Alcresta Therapeutics Inc.
• Vivus Inc.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 체외분비 기능부전(EPI) 치료 및 진단 시장 : 새로운 기회를 제공하는 국가(2029년)
• 체외분비 기능부전(EPI) 치료 및 진단 시장 : 새로운 기회를 제공하는 부문(2029년)
• 체외분비 기능부전(EPI) 치료 및 진단 시장 : 성장 전략(2029년)
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The growing prevalence of diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic condition characterized by elevated blood sugar levels (hyperglycemia), resulting from the body's inability to produce sufficient insulin or use the insulin effectively. EPI treatment, including pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and support better glycemic control in individuals with both diabetes and EPI. For example, in June 2024, the National Health Service (NHS England) reported that the number of people diagnosed with pre-diabetes in 2023 increased to 3,615,330, an 18% rise from 3,065,825 in 2022. Among those under 40, pre-diabetes cases rose nearly 25%, from 173,166 in 2022 to 216,440 in 2023. This growing diabetic population is fueling the demand for EPI therapeutics and diagnostics.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly forming strategic partnerships to integrate advanced technologies and broaden their market presence. A strategic partnership involves collaboration between two or more organizations, combining their resources, expertise, and efforts to reach shared objectives. For example, in February 2023, Codexis, Inc., a protein engineering firm based in the US, partnered with Nestle Health Science, a Swiss nutrition company, to announce the interim results of their Phase 1 clinical trial of CDX-7108, an investigational therapy for EPI. These promising results from the trial open the door for further research that could lead to improved treatment options for individuals affected by EPI.

In October 2022, DiaSorin SpA, an Italian biotechnology firm, acquired Luminex Corporation for $1.8 billion. This acquisition allows DiaSorin to bolster its presence in the U.S. market, expand its product portfolio, and establish long-term collaborations with biopharmaceutical companies. Luminex Corporation, based in the U.S., specializes in biological testing technologies, including those related to exocrine pancreatic insufficiency (EPI).

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
• 2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
• 3) By Drug Type: Generic; Branded
• 4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
• 5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
• Subsegments:
• 1) By Nutritional Management: Dietary Modifications; Nutritional Supplements
• 2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations; Tablet Formulations; Powder Formulations
• 3) By Lifestyle Modifications Approach: Weight Management; Physical Activity Recommendations; Smoking Cessation Programs
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Rate Analysis
• 5.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Total Addressable Market (TAM)

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

• 6.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)
• Lifestyle Modifications Approach
• 6.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Magnetic Resonance Imaging (MRI)
• Endoscopic Ultra-Sonography (EUS)
• Computerized Tomography (CT) Scanning
• 6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic
• Branded
• 6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Retail Pharmacy
• Third-Party Distributor
• Other Distribution Channels
• 6.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Diagnostic Center
• Research And Academic Institutes
• Other End Users
• 6.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Nutritional Management, BY Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Modifications
• Nutritional Supplement
• 6.7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsule Formulations
• Tablet Formulations
• Powder Formulations
• 6.8. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Lifestyle Modifications Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Weight Management
• Physical Activity Recommendations
• Smoking Cessation Programs

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

• 7.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 9.1. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 9.2. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 10.1. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 11.1. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 11.2. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 12.1. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 13.1. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 14.1. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 14.2. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 15.1. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 15.2. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 16.1. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 17.1. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 18.1. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 19.1. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 20.1. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 21.1. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 21.2. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 22.1. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 23.1. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 23.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 24.1. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 24.2. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 25.1. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 25.2. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 26.1. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 26.2. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 27.1. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 28.1. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 28.2. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

• 29.1. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
• 29.2. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape
• 30.2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Abott Laboratories
• 31.4. Medtronic plc
• 31.5. Solvay S.A.
• 31.6. Laboratory Corporation of America Holdings (Labcorp)
• 31.7. Organon group of companies Metagenics LLC
• 31.8. Allergan plc
• 31.9. Chiesi Farmaceutici S.p.A.
• 31.10. Codexis Inc.
• 31.11. Nordmark Arzneimittel GmbH & Co. KG
• 31.12. ChiRhoClin Inc.
• 31.13. Digestive Care Inc.
• 31.14. Alcresta Therapeutics Inc.
• 31.15. Vivus Inc.

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

34. Recent Developments In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료